Single-cell epigenetic profiling reveals an interferon response-high program associated with BAP1 deficiency in kidney cancer.

Autor: Camp SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., He MX; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Harvard Graduate Program in Biophysics, Boston, MA 02115, USA., Cuoco MS; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Bioinformatics and Systems Biology Graduate Program, University of California, San Diego, CA 92093, USA., Saad E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Pimenta E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Meli K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Harvard Division of Medical Sciences PhD Program in Biological and Biomedical Sciences, Boston, MA 02115, USA., Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065., Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Titchen BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Harvard Division of Medical Sciences PhD Program in Biological and Biomedical Sciences, Boston, MA 02115, USA., Kang YJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA., Horst J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Trowbridge R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Shannon E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Helvie K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Thorner AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Vigneau S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Mayorga A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Kodali J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lachmayr H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Bemus M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Choueiri T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Bi K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Nov 18. Date of Electronic Publication: 2024 Nov 18.